Author

Jay D. Nelson

Observed name: J. Nelson

Institution: Ambrx (United States)

Observed institution: Ambrx (United States)

ORCID: 0009-0005-8071-4592

Observed ORCID: 0009-0005-8071-4592

OpenAlex ID: A5078065627

Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2024 · Lillian K. Skidmore, David Mills, et al. · Molecular Cancer Therapeutics · 24

Data from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2024 · Lillian K. Skidmore, David Mills, et al.

Table S1 from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2024 · Lillian K. Skidmore, David Mills, et al.

Toxicity Profile of Isis 2503, a Phosphorothioate Oligodeoxynucleotide Targeted to Human H-ras

1997 · M. V. Templin, D. M. Monteith, et al. · Journal of Immunotherapy

Works count: 4

Citation count: 24

H-index: 1

I10-index: 1